Cummings, J; Zweifel, M; Smith, N; Ross, P; Peters, J; Rustin, G; Price, P; Middleton, M R; Ward, T; Dive, C (2012). Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. British journal of cancer, 106(11), pp. 1766-71. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.165
Full text not available from this repository. (Request a copy)OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Zweifel, Martin |
ISSN: |
0007-0920 |
Publisher: |
Nature Publishing Group |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:36 |
Last Modified: |
05 Dec 2022 14:11 |
Publisher DOI: |
10.1038/bjc.2012.165 |
PubMed ID: |
22538971 |
Web of Science ID: |
000304353500009 |
URI: |
https://boris.unibe.ch/id/eprint/14286 (FactScience: 221162) |
Actions (login required)
 |
Edit item |